Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Comparison of CD34 + cell mobilization, blood graft cellular composition, and post‐transplant outcome in myeloma patients mobilized with filgrastim or pegfilgrastim added to low‐dose cyclophosphamide: A prospective multicenter study

Autor: Kuittinen Taru, Mäntymaa Pentti, Siitonen Timo, Penttilä Karri, Pelkonen Jukka, Putkonen Mervi, Valtola Jaakko, Varmavuo Ville, Turunen Antti, Silvennoinen Raija, Sankelo Marja, Pyörälä Marja, Partanen Anu, Jantunen Esa, Sikiö Anu

Publikováno v: Transfusion. 61:3202-3212

Background Scarce data exist on the impact of granulocyte-colony stimulating factor (G-CSF) type on the mobilizing capacity of CD34+ cells, graft cellular composition, and outcome in myeloma (MM) patients. Patients and methods In this prospective mul

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8b8c68f9e6b088fa3cd7e6bae8fd5d1c
https://doi.org/10.1111/trf.16645

Carfilzomib, Elotuzumab and Dexamethasone for Relapsed or Refractory Myeloma Patients

Autor: Silvennoinen, Raija Helena, Nahi, Hareth, Anttila , Pekka, Koskenvesa, Perttu, Lievonen, Juha, Marttila, Anu, Varmavuo, Ville, Sikiö, Anu, Nurmi, Marita, Säily, Marjaana, Partanen, Anu, Sankelo, Marja, Luoma, Sini, Mäntymaa, Pentti, Ilveskero, Sorella, Eshoj, Henrik, Kongsgaard Nielsen, Lene, Jantunen, Esa, Heckman, Caroline

Publikováno v: Silvennoinen, R H, Nahi, H, Anttila, P, Koskenvesa, P, Lievonen, J, Marttila, A, Varmavuo, V, Sikiö, A, Nurmi, M, Säily, M, Partanen, A, Sankelo, M, Luoma, S, Mäntymaa, P, Ilveskero, S, Eshoj, H R, Nielsen, L K, Jantunen, E & Heckman, C 2020, ' Carfilzomib, Elotuzumab and Dexamethasone for Relapsed or Refractory Myeloma Patients ', Blood, bind 136, nr. Supplement 1, 20 . https://doi.org/10.1182/blood-2020-138447
Silvennoinen, R H, Nahi, H, Anttila, P, Koskenvesa, P, Lievonen, J, Marttila, A, Varmavuo, V, Sikiö, A, Nurmi, M, Säily, M, Partanen, A, Sankelo, M, Luoma, S, Mäntymaa, P, Ilveskero, S, Eshoj, H, Kongsgaard Nielsen, L, Ilveskero, S, Jantunen, E & Heckman, C 2020, ' Carfilzomib, Elotuzumab and Dexamethasone for Relapsed or Refractory Myeloma Patients ', Blood, vol. 136, no. Suppl. 1, 20 . https://doi.org/10.1182/blood-2020-138447

Introduction: Due to its heterogenous nature including evolving mutations, multiple myeloma (MM) is still an incurable disease. Several novel agents have been introduced during the last decade resulting in prolonged median overall survival (OS) up to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4be1bc46f1a34eca20ae61ed5e81f3fc
https://pure.au.dk/portal/da/publications/carfilzomib-elotuzumab-and-dexamethasone-for-relapsed-or-refractory-myeloma-patients(3240504a-3c7b-419a-93ca-f86c08a7f71b).html

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

P-222: A prospective phase 2 study to assess minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible multiple myeloma patients

Autor: Silvennoinen, Raija, Waage, Anders, Peceliunas, Valdas, Schjesvold, Fredrik, Anttila, Pekka, Uttervall, Katarina, Säily, Marjaana, Putkonen, Mervi, Carlson, Kristina, Haukas, Einar, Sankelo, Marja, Partanen, Anu, Szatkowski, Damian, Hansson, Markus, Marttila, Anu, Svensson, Ronald, Axelsson, Per, Lauri, Birgitta, Mikkola, Maija, Karlsson, Conny, Abelsson, Johanna, Ahlstrand, Erik, Sikiö, Anu, Nahi, Hareth

Publikováno v: In Clinical Lymphoma, Myeloma and Leukemia August 2022 22 Supplement:S157-S157